Abstract
Lymphatic vessels provide an anatomical framework for immune surveillance and adaptive immune responses. Though appreciated as the route for antigen and dendritic cell transport, peripheral lymphatic vessels are often not considered active players in immune surveillance. Lymphatic vessels, however, integrate contextual cues that directly regulate transport including changes in intrinsic pumping and capillary remodeling and express a dynamic repertoire of inflammatory chemokines and adhesion molecules that facilitates leukocyte egress out of inflamed tissue, and these mechanisms all together contribute to the course of peripheral tissue immunity. In this review, we focus on context-dependent mechanisms that regulate fluid and cellular transport out of peripheral non-lymphoid tissues to provide a framework for understanding the effects of afferent lymphatic transport on immune surveillance, peripheral tissue inflammation, and adaptive immunity.
Keywords: lymphatic vessels, afferent lymph, immune surveillance, transport, leukocyte egress
The lymphatic system is composed of a hierarchy of lymphatic vessels that transport lymph unidirectionally to lymph nodes (LNs) and the specialized lymphatic endothelial cells (LECs) that compose both these vessels and LN lymphatic networks. Blunt ended lymphatic capillaries are composed of a single layer of LECs anchored to extracellular matrix (ECM) fibers and extend into peripheral tissues to facilitate uptake of fluid, cells, and lipids. Collecting vessels, differentiated from capillaries by the investment of lymphatic muscle cells (LMCs), a continuous basement membrane, and valves, contract to generate intrinsic propulsive forces that transport lymph to LNs and prevent retrograde flow. The structure and function of lymphatic vessels as it varies across organ sites in health and disease was recently covered in two excellent reviews (1, 2). Here we focus on the role of afferent lymphatic transport in peripheral tissue immune responses.
Lymphatic transport and interstitial fluid dynamics regulate the physiological context of peripheral tissues at steady state and in response to challenge (e.g. infection, wound healing, tumor formation). Peripheral tissues receive necessary nutrients and oxygen from vascular transudate, which drives a net excess of fluid within tissue interstitium, generating directional interstitial fluid flows (0.1–1.0 μm/s) toward lymphatic capillaries (3). At steady state, the sparse basement membrane and discontinuous intercellular junctions (termed button-like junctions) found in lymphatic capillaries allow passive, paracellular fluid transport to form lymph (4, 5). In addition to the movement of fluid, the distribution of signaling molecules, cytokines, and antibodies is biased towards lymphatic transport dependent upon oncotic pressure gradients that limit vascular reabsorption. Large particulates, such as exosomes, chylomicrons, and protein complexes, must enter lymphatic vessels to access the systemic circulation (6). Lymph formation is further supported by active endocytic and transcellular LEC transport (7) and, as a net result, lymph is composed of a unique repertoire of tissue-derived lipids, metabolites, soluble proteins, and antigens that reflects the immunological status of the tissue from which it originates (8). Upon arrival in LNs, lymph and its constituents orchestrate the rapid activation of adaptive immune responses where both the functional heterogeneity of LN LECs (9) and fluid transport (10) directly impact antigen distribution, presentation, and leukocyte interactions.
Here we provide an overview of afferent lymphatic transport during peripheral tissue immune responses. We discuss our current understanding of how lymphatic vessels move fluid and leukocytes out of resting and inflamed tissue, how lymphatic transport is affected by inflammatory context, and how it contributes to immune surveillance, adaptive immune activation, and resolution in peripheral non-lymphoid tissue.
Immune Surveillance
Through the constitutive transport of lymph, memory lymphocytes, and antigen presenting cells (APCs), the afferent lymphatic vasculature provides the anatomic framework for immune surveillance in peripheral, non-lymphoid tissues (Figure 1), defined here as the initial detection of pathogenic or inflammatory insult. The observation that afferent lymph harbors a significant population of migratory leukocytes distinct from those found in blood and efferent lymph was made decades ago following cannulation of ovine afferent lymphatic vessels (11, 12), and similar findings have been reported in mice (13, 14) and humans (15, 16). These early studies profiled afferent lymph across tissues and demonstrated a relatively constant proportion of mature lymphocytes (80–90%), myeloid cells (5–20%), and various granulocytes and plasma cells in sheep (11) and mice (17). Lymph-borne lymphocytes at steady state are predominantly of a memory phenotype and mostly CD4+ (including regulatory T cells from skin (18)), though also include B cells, CD8+ and γδ T cells (19). In contrast, naïve T cells are largely excluded from non-lymphoid peripheral tissue draining lymph, with the exception of gut (19, 20), where Peyer’s patches likely provide a source of naïve T cells that enter afferent lymph. Importantly, the recirculation of memory lymphocytes provides the opportunity for rapid response to secondary challenge, whereas migratory APCs amplify memory and activate de novo responses in LNs to drive protective adaptive immune responses.
Figure 1. The lymphatic anatomy of immune surveillance.
Under basal conditions, immune surveillance is regulated by constitutive lymph transport and the trafficking of lymphocytes (naive, memory and regulatory) and antigen presenting cells between peripheral tissue, lymphoid, and systemic compartments. Vascular transudate generates directional interstitial fluid flows in the direction of draining, low pressure lymphatic capillaries, where open, discontinuous button-like junctions (dotted red lines) facilitate passive uptake and permit integrin-independent cell transmigration. Oncotic gradients and interstitial fluid flow (0.1–1 μm/s) enrich afferent lymph for tissue-derived factors, antigens, large particulates, and protein complexes that reflect the immunological status of the tissue from which it drains. Collecting lymphatic vessels propel fluid towards draining lymph nodes through intrinsic pumping mechanisms regulated by invested LMCs, and continuous zipper-like intercellular junctions (solid red lines) restrict vessel permeability. Leukocytes migrating through afferent lymph are predominantly of memory and regulatory phenotypes, distinct from both efferent lymph and blood where naive T cells also recirculate in search of cognate antigen loaded on migratory DCs and other antigen presenting cells. Resident memory T cells are defined by their exclusion from afferent lymph and long-term retention in peripheral, non-lymphoid tissue at basal conditions. Dendritic cells (DC); naive T cells (TN); memory T cells (TMem); resident memory T cells (TRM); regulatory T cells (TREG); lymphatic muscle cell (LMC).
Lymph Transport to Lymph Nodes
In response to peripheral tissue challenge, pro-inflammatory mediators activate the vascular endothelium, increasing permeability and fluid influx that drives tissue swelling. Accumulation of interstitial fluid (termed edema) is itself a critical feature of host defense as it directly promotes effector molecule (e.g. immunoglobulins and complement) accumulation, and thereby facilitates local inflammation, pathogen control, and adaptive immunity (21). Multiple overlapping signals regulate vascular permeability (reviewed (22)). Mast cells, for example, produce histamine that activates type I histamine (H1) receptor leading to Src-mediated tyrosine phosphorylation of adherens junction molecules, VE-cadherin and β-catenin (23). Disruption of tight and adherens junctions disrupts the size exclusion properties of post-capillary venules allowing for the influx of larger macromolecules. The importance of vascular permeability is highlighted in mouse models of Herpes Simplex Virus Type 2 (HSV-2) and Vesicular Stomatitis Virus (VSV) infection, where production of IFNγ by memory CD4+ T cells increases vascular permeability, which is necessary for antibody access to infected neuronal tissue and viral control (24). While increased vascular permeability enhances tissue access, the extent to which fluid and effector molecules accumulate in the interstitial space also depends on local lymphatic transport.
In response to increased interstitial fluid load and inflammatory mediators, lymphatic vessels can adapt their intrinsic pumping activity to both increase and decrease transport dependent on context. In lymphatic vessels of the guinea pig mesentery histamine increases the frequency of collecting lymphatic constriction by activating LMC H1 receptors (25). In contrast, histamine may also act through H1 receptors expressed by LECs to cause nitric oxide (NO)-dependent relaxation (26, 27), and stimulation of LMC H2 induces relaxation that may reduce fluid flows at least in a subset of vessels of the mesentery (25). Imposed fluid flow through ex vivo mesenteric lymphatic vessel explants also induces NO production and subsequently reduces, rather than elevates, collecting lymphatic contraction and pumping (28). In vivo, lymph stasis, initiated by a surgical model of persistent mouse tail lymphedema, drives the accumulation of Th2 CD4+ T cells (29) that inhibit collecting lymphatic pumping through local activation of macrophage inducible nitric oxide synthase (iNOS) (30) and exacerbate local pathology. While increased intrinsic pumping would presumably counteract vascular permeability and reduce edema, a decrease in pumping may limit transport to LNs. To this point, during oxazolone treatment of skin, a rapid, transient reduction in collecting lymphatic vessel contraction, dependent upon the overproduction of NO by CD11b+Gr1+ myeloid cells, transiently decreases antigen-loaded dendritic cell (DC) accumulation in LNs and impairs induction of experimental autoimmune encephalomyelitis (31). Therefore, it appears as though local inflammatory mediators act in coordination with lymphatic transport to affect tissue physiology and the kinetics of antigen presentation in LNs. How inflammatory context (e.g. infection vs allergy) may differentially affect collector contraction within various tissue sites, remains an important question moving forward.
The contextual plasticity of collecting lymphatic vessels, described above, is progressively lost with age (32) and may be disrupted by infection. Cutaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) results in an acute reduction in lymphatic vessel contractility and lymph flow that persists long after MRSA infection and inflammation are resolved due to a permanent loss of LMCs (33). In the gut, Yersinia pseudotuberculosis infection induces persistent local inflammation driven by lymphatic leakage in mesenteric adipose tissue and impaired DC migration to LNs (34). Consistent with these preclinical findings, patients with lymphedema exhibit increased risk for skin and soft tissue infections and conversely, lymphedema can arise as a consequence of infection (35, 36), suggesting the possibility of regional changes in lymphatic transport that have long-lasting effects on local immune surveillance.
In addition to inflammation and flow-mediated changes to collecting lymphatic contraction, recent evidence indicates that lymphatic capillaries are responsive to inflammatory context and may remodel their interendothelial junctions to regulate paracellular transport. Lymphatic capillary junctions, normally discontinuous (buttons), become continuous (zippering) during Mycoplasma Pulmonis (M. pulmonis) infection of the trachea and lose the loose, interendothelial flaps presumed to facilitate passive fluid and cellular uptake (37). The intestinal lacteal, a specialized lymphatic capillary of the small intestine, exhibits a similar zippering phenotype following antibiotic depletion of commensal microbiota (38) or increased bioavailability of vascular endothelial growth factor (VEGF-A) (39), in both cases leading to impaired dietary lipid absorption. During cutaneous Vaccinia virus (VACV) infection, a rapid reduction in lymphatic transport is dependent upon type I IFN signaling, and associated with elongation of lymphatic capillary blunt ends and viral retention within skin (40). Peripheral lymphatic capillaries are therefore sensitive to changing context and may determine differential transport of fluid and soluble macromolecules that impacts immune surveillance. How lymphatic capillary zippering is regulated across diverse peripheral tissues and its physiological relevance in vivo, however, remains to be carefully dissected in a cell-specific manner.
Dendritic Cell Trafficking via Afferent Lymphatic Vessels
While lymph flow can deliver soluble antigen to LNs in minutes (41–44), the data discussed above suggest the possibility that under certain inflammatory contexts, lymphatic vessel-intrinsic mechanisms reduce fluid transport and thereby may impact the kinetics of antigen presentation in LNs. Interestingly, though fluid flow is reduced following VACV infection by scarification, DCs continue to migrate across inflamed lymphatic vessels and prime CD8+ T cells in draining LNs (40). Similarly, while subcutaneous injection of HSV-1 leads to rapid virion transport to LNs and antigen presentation by resident DCs, CD8+ T cell activation following vaginal administration depends specifically on migratory DCs (45). Therefore, how lymphatic vessels actively regulate the specific transport of DCs, in concert with fluid transport, likely determines the kinetic of adaptive immune priming in LNs.
The migration of mature DCs to LNs is regulated at each step by the lymphatic vasculature, which provides directional cues to increase the probability that antigen-loaded DCs reach their cognate T lymphocytes in LNs. While interstitial fluid flows are slow (0.1–1μm/s) (46), they are sufficient to bias interstitial gradients (47, 48), influence matrix remodeling and orientation (49, 50), and activate adhesive properties and chemokine secretion in draining lymphatic vessels (51). These mechanisms together collaborate to facilitate directional DC migration towards draining lymphatic capillaries in peripheral, non-lymphoid tissue. DC migration is importantly largely, though not exclusively, dependent upon the homeostatic chemokine CCL21, which is expressed by LECs, required for CCR7-dependent homing (52), and elevated by inflammatory cytokines, such as TNF-ɑ (53, 54), and inflammatory fluid flows (48, 50, 54). DCs increase CCL21 production by LECs during transmigration that supports subsequent waves of DC migration (55–57). Interestingly, the cytoplasmic tail of programmed death-ligand 1 (PD-L1) on conventional type 1 (cDC1) and type 2 (cDC2) dermal DCs reinforces G-coupled protein receptor signaling and enhances CCR7-directed LN migration via CCL21 gradients (58), suggesting there are multiple, intrinsic and extrinsic mechanisms that regulate the lymphatic migration of DCs. Importantly, CCR7-dependent DC migration is required for antigen presentation to naive CD8+ T cells from skin during HSV-1 infection and following DC adoptive transfer (45, 53, 59, 60); for presentation of intestinal epithelial cell-derived antigens from lamina propria in mesenteric LNs (61); and presentation of tumor antigen by cross-presenting cDC1s in tumor-draining LNs (62, 63).
Interestingly, however, during allergic sensitization, cDC2s can migrate to LNs in a CCR7-independent manner (64), suggesting that mechanisms of lymphatic homing and migration may be cell type and state specific. Given that LECs activate specific secretion profiles in response to inflammatory cytokines (type 1, 2, 17, etc) (65, 66) and toll-like receptor stimulation (67), it is possible that a dynamic LEC chemokine repertoire may preferentially support the tissue exit of specific DC subtypes in a context-dependent manner. To this point, dermal LECs secrete CXCL12 in response to cutaneous irritants such as 2,4-dinitrofluorobenzene, which drives CXCR4+ DC exit including langerin+/−, CD11c+, and CD11b+ subsets (68), and CX3CL1 stimulated by oxazolone treatment recruits CX3CR1+CD11c+ dermal DCs (54). The signaling sphingolipid, sphingosine-1-phosphate (S1P), is required for lymphocyte egress from lymphoid tissues (69), but may also play a role in mediating DC egress from peripheral tissues such as skin and lung (70, 71). Lymph S1P is maintained by LECs (72, 73) and migratory DCs show a tissue-specific requirement for the S1P receptors. Dermal DCs seem to rely only on S1P1 to migrate to draining LNs following topical application of FITC in organic solvents, whereas both S1P1 and S1P3 are required for the accumulation of CD103+ DCs in mesenteric LNs draining LPS-inflamed gut (74).
In addition to producing chemotactic gradients, peripheral LECs express several atypical chemokine receptors (ACKRs), including ACKR2 and ACKR4, that scavenge inflammatory chemokines to shape interstitial gradients, which may amplify directional cues. ACKR4, expressed by dermal LECs and keratinocytes, scavenges excess CCL19, another CCR7-binding chemokine, to improve CCL21-dependent homing of CCR7+ Langerhan cells to lymphatic vessels following cutaneous terephthalic acid application (75); and ACKR2 (also known as D6 and expressed by dermal LECs (76, 77)) scavenges CCL2 and may promote the migration of DCs by preventing the perilymphatic accumulation of CCR2+ inflammatory myeloid cells (78). Inflammatory chemokine scavenging by the afferent lymphatic endothelium may also prevent persistent LN activation. Indeed, mice lacking ACKR2 display exacerbated inflammatory responses following subcutaneous administration of complete Freund’s adjuvant (CFA) (79).
At steady state, the permissive nature of lymphatic capillary interendothelial “button” junctions allows for integrin-independent DC transendothelial migration across the lymphatic endothelium (5, 80). However, the lymphatic capillary zippering observed in some infection and inflammatory contexts (37), may presumably remove these passive portals and thus increase the requirements for DC transmigration (5). To support DC transendothelial migration, inflammatory cytokines including TNF-ɑ and IL-1β (81–83), and transmural fluid flows (51) induce expression of cellular adhesion molecules including ICAM-1, VCAM, and selectins. Though shear stresses are much lower in lymphatic capillaries as compared to blood, active binding through cell adhesion molecules and selectins is still required for DC entry into inflamed dermal lymphatic capillaries (51). Both antibody blockade and genetic ablation of ICAM-1, VCAM or their respective integrin ligands (LFA-1 and CD11b) significantly reduces dermal DC migration to LNs in several models of skin inflammation (81, 84, 85) and inhibits adaptive immune responses (86). The hyaluronan (HA) binding lymphatic vessel endothelial receptor 1 (LYVE-1), expressed by lymphatic capillaries, facilitates HA-dependent DC docking and transendothelial migration under inflammatory contexts and LYVE1-deficient animals exhibit reduced CD8+ T cell priming following vaccination (87). Owing to the low shear stresses in lymphatic capillaries, intraluminal DCs exhibit a slow, semi-directional, ICAM-1 dependent crawling behavior (88). This proceeds until DCs reach collecting vessels (89) where elevated shear stresses are hypothesized to downregulate adhesion molecules to permit flow-induced transport to LNs (90). While the immunological consequences of intralymphatic crawling are unknown, it may suggest that the lumen of lymphatic capillaries is a specialized niche wherein prolonged interactions between DCs, lymphocytes (91), and LECs occur that may have functional consequences for immune responses (83).
Peripheral Tissue Inflammation and Leukocyte Egress
The number of leukocytes present in afferent lymph increases during acute and chronic inflammation (13, 92, 93), indicating a dynamic process of tissue exit that may contribute to peripheral tissue inflammation. Like fluid transport, leukocyte egress is likely critical for the removal of pro-inflammatory signals that would otherwise exacerbate tissue inflammation and immunopathology. Multiple studies indicate that the induction of lymphangiogenesis by the lymphangiogenic growth factor, VEGF-C, in chronically inflamed tissues (e.g. dextran sulfate sodium-induced colitis, psoriasis-like cutaneous inflammation, and tumors) increases fluid and leukocyte transport out of tissue and thereby reduces ongoing inflammatory processes (94–96). Similarly, during cutaneous Leishmania major infection, VEGF-A-induced lymphangiogenesis restricts lesion formation without affecting parasite burden by reducing inflammatory lesion size (97).
While it is clear that multiple cell types are capable of accessing afferent lymph, the mechanisms that direct the egress of diverse leukocyte subtypes have only been examined in a handful of tissue and inflammatory contexts. Still, these data indicate interesting cell type and tissue state specificity. For example, neutrophils use CCR7 to egress acutely inflamed skin (CFA) (98) and cremaster muscle (99), but CXCR4 and CD11b to reach LNs following cutaneous Staphylococcus aureus infection, where they boost T cell proliferation in draining LNs (100). ICAM-1 and its cognate ligands are required for neutrophil transendothelial migration in several contexts including CFA-induced inflammation and Mycobacterium bovis infection of skin (101, 102). B cells also exhibit elevated rates of egress from chronically CFA-inflamed skin (103) via both CCR7-dependent and independent mechanisms (104); and entrance of monocytes and macrophages into afferent lymph (105–108) is inhibited by integrin ɑ1β1 in concanavalin A inflamed skin (109).
T cell Egress from Inflamed Peripheral Tissue
The abundance of T cells in afferent lymph and their critical role in immune surveillance and adaptive immunity has encouraged more studies examining mechanisms of T cell exit from inflamed tissues, particularly from skin. While it appears that multiple mechanisms may regulate CD4+ and CD8+ T cell egress via lymphatic vessels (Figure 2), as with DCs, the predominant pathway studied to date is CCL21-CCR7, which is required for egress at both steady state (110) and during acute inflammation in lung (111, 112) and skin (104). CCR7-deficient CD4+ Th1 cells dramatically accumulate in skin and exacerbate pathology associated with delayed-type hypersensitivity responses (113) and transgenic expression of CCR7 in CD4+ T cells is sufficient to enhance egress from lung following antigen challenge (111). Therefore, T cell egress through lymphatic vessels may provide an important control point to balance protective immunity with damaging immunopathology. The mechanisms that regulate T cell egress, however, seem to vary by context. CD4+ and CD8+ T cell exit from chronically inflamed skin and tumors appears to be CCR7-independent (13, 114), however, the signals that direct exit in this context remain unknown (115). In addition to chemokines, T cells use multiple adhesion molecules to facilitate transendothelial migration including common lymphatic endothelial and vascular endothelial receptor-1 (116)), ICAM-1 (84) and macrophage mannose receptor-1, which facilitates interactions with lymphocyte CD44 (117); though when, where, and for which subsets each of these are used remains incompletely understood. In addition to ɑβ T cells, γδ T cells are found in afferent lymph draining resting (19, 118), inflamed (119), and malignant (114, 120) tissues. Important surveyors of peripheral non-lymphoid tissue, γδ T cells are presumed to exit tissue via CCR7-independent mechanisms owing to a lack of CCR7 surface expression in bovine (118) and ovine lymph (119); here high expression of E-selectin and CCR6-dependent chemotaxis towards CCL20 may indicate alternative mechanisms of lymphatic homing (119). These mechanisms, however, have not been tested functionally in vivo.
Figure 2. T cell egress from peripheral tissues via lymphatic capillaries.
Peripheral lymphatic capillaries mediate the directional homing and transmigration of T lymphocytes from steady state and inflamed peripheral tissues. (1) Under basal conditions, the trafficking of memory and regulatory lymphocytes is largely dependent on the homeostatic chemokine, CCL21, constitutively expressed by peripheral lymphatic capillaries. (2) Inflammatory cytokines, such as TNFɑ and IL-1β, activate regional blood and lymphatic vessels, increasing vascular permeability, interstitial fluid flow, and inducing lymphatic endothelial production of a diverse repertoire of chemokines and adhesion molecules that presumably direct the egress of T cells. Activated CD4+ and CD8+ effector T cells are recruited to inflamed peripheral tissues where recognition of cognate antigen, downregulates lymphatic homing receptors (S1PRs and CCRs), supports tissue retention, and ultimately long-term residence as TRM. IFNγ produced by antigen-specific CD8+ T cell responses further activates the lymphatic vasculature to induce expression of MHCII and PD-L1, which may act to negatively regulate ongoing cytotoxic immunity. Active mechanisms increase the overall abundance of lymph-borne lymphocytes. (3) S1P acts both on CD4+ T cells, which use S1P1 and S1P4 to enter afferent lymph, and lymphatic endothelial cells where S1P2 regulates VCAM expression and transendothelial migration. Additionally, during acute inflammatory processes in skin, CCR7 and ICAM-1 is required for T cell egress via lymphatic vessels, while CCR7-dependence is lost in chronic inflammation. (4) In grafts, TREG cell migration to lymph nodes is necessary to limit alloimmune responses and transmigrating TREG condition the lymphatic endothelium to express higher levels of VCAM through activation of LTβR that supports subsequent egress of inflammatory lymphocytes (CD4+ and CD8+ T cells) to resolve peripheral tissue inflammation. (5) Lymphatic capillaries also directly regulate peripheral tissue inflammation by scavenging inflammatory chemokines through expression of decoy receptors (ACKR2/D6) limiting their effect in peripheral tissue and transport to lymph nodes. Memory T cells (TMem); effector T cells (TEff); resident memory T cells (TRM); regulatory T cells (TREG); antigen presenting cell (APC).
In addition to chemokines, S1P may play an important role in T lymphocyte egress from tissue (121). Effector and memory CD4+ T cells respond to S1P gradients in vitro and require S1P1 and S1P4 for migration into lymphatic vessels following co-injection with LPS (122). Interestingly, S1P1 and S1P4 appear to exhibit non-redundant roles and coordinate with S1P2 on lymphatic vessels to activate adhesive sites for transendothelial migration (122). This highlights the important fact that S1P also regulates endothelial cell homeostasis (123, 124), which should be considered when manipulating S1P signaling in vivo. Consistent with the hypothesis that S1P regulates T cell exit from tissue, S1P receptors are transcriptionally repressed in tissue resident memory T cells (TRM) (125, 126) and enforced S1pr1 expression reduces resident memory formation by CD8+ T cells (126). S1P receptor stimulation and desensitization through application of the small molecule FTY720, is sufficient to reduce CD4+ T cell egress to LNs (121), and rescues CD69−/− retention in skin following HSV-2 infection (127). FTY720-treated CD4+ T cells notably arrest their migration at the basal surface of lymphatic monolayers in vitro and capillaries in vivo (121), perhaps suggesting that chemokine receptors (e.g. CCR7) generate directional gradients whereas S1P signaling acts in coordination with cell adhesion molecules to facilitate transendothelial migration. Interestingly, antigen recognition in peripheral, non-lymphoid tissue boosts tissue retention (112, 113) and the formation of tissue resident memory (128). Consistent with this, influenza virus-specific T cells are largely CCR7−/− in lung (111, 129) and TCR stimulation is sufficient to modulate surface expression of CCR7 (130). Taken together, the antigen-dependence of T cell egress might contribute to the focusing of the interstitial T cell repertoire through combined S1P and CCR7-dependent signals to promote the recirculation of bystander T cells while limiting overt pathology. How local antigen, inflammatory context, and lymphatic-derived signals may over time regulate interstitial T cell repertoires and contraction to memory is an interesting area for continued study.
Interestingly, peripheral lymphatic vessels are responsive to cytokines derived from infiltrating and transmigrating T lymphocytes and subsequently adapt their surface expression and function. Regulatory T cells (TREG), which migrate from skin during steady state, show increased migration during CHS inflammation and migratory TREG exhibit more potent suppressive activity when compared to LN resident TREG cells (18). Similarly in allograft models, TREG cell egress suppresses alloimmune responses and improves graft survival (131). Interestingly, TREG cells activate lymphotoxin β receptor (LTβR) signaling in LECs to specifically facilitate their VCAM-dependent egress from grafted tissue (132), and, in so doing, also condition LECs to increase expression of CCL21 that supports subsequent effector CD4+ and CD8+ T cell migration (133). This resolves the allograft response by both removing excessive inflammatory cells (e.g. CD4+ and CD8+ T cells, neutrophils, and macrophages) and inhibiting activation in LN. Furthermore, IFNγR signaling in lymphatic capillaries seems to limit effector T cell responses in both infected and malignant skin (134). IFNγ drives expression of both MHCII and PD-L1 on peripheral lymphatic capillaries (134), which may indicate the potential for direct signaling between T lymphocytes and inflamed capillaries, consistent also with prior observations that peripheral lymphatic vessels can scavenge and cross-present tumor-derived antigens (94). How the crosstalk between accumulating lymphocytes and lymphatic vessels contributes to ongoing inflammatory processes remains to be systematically dissected across tissue sites, but these studies indicate that it may have significant implications for local pathology and disease control.
Inflammatory Lymphangiogenesis
Importantly, the mechanisms discussed above may all be influenced by the progressive lymphatic vessel remodeling observed in inflamed tissues. Tissue-infiltrating macrophages secrete VEGF-C and drive local lymphangiogenesis in tumors (135, 136) and experimental inflammatory models in gut and skin (95, 96, 137). Under chronic conditions, lymphatic vessels are often dilated and leaky (95, 138), which can ultimately lead to poor tissue clearance (33, 139) and thus exacerbate local pathology. Importantly, whether once expanded, lymphatic networks contract as inflammation resolves remains poorly understood. In LNs, LECs undergo extensive inflammatory lymphangiogenesis in part driven by B cell-derived VEGF-A (140) and contract post-inflammation in an IFN-dependent manner (141, 142). However, the extent to which lymphangiogenic vessels in non-lymphoid peripheral tissues contract post-inflammation appears both tissue-specific and dependent on the inflammatory insult itself. Airway lymphatic networks remain expanded for several months after M. pulmonis clearance and are resistant to dexamethasone treatment (143); and transgenic VEGF-C expression leads to persistent durable lymphatic hyperplasia in skin (144). In contrast, lymphangiogenic corneal networks completely regress following sterile injury (145, 146), and surprisingly exhibit accelerated lymphangiogenic responses following repeated challenge (147), perhaps suggesting a type of inflammatory memory (148). How the immunological experience of a peripheral tissue may lay the groundwork for future regional immune responses through long-lasting changes in lymphatic morphology and transport, particularly in barrier tissues, will continue to be an exciting area of study.
Conclusions
As this field grows, it becomes increasingly clear that lymphatic vessels and their associated transport properties directly contribute to immune homeostasis and disease through multiple overlapping and context-dependent mechanisms. As the exquisite phenotypic and functional heterogeneity of lymphatic vessels is revealed, both within and across tissues, we are in critical need of functional studies that dissect the relative contribution of distinct LEC subsets and pathways to immunity with anatomic resolution in vivo. These mechanisms will inform therapeutic strategies to leverage lymphatic biology for immune benefit in patients across disease type.
There is already growing interest in identifying strategies that boost immune surveillance or alter peripheral tissue inflammation through the manipulation of resident lymphatic vessels. This is particularly true in the context of cancer where it was first shown in melanoma (149) and subsequently in glioblastoma (150) that overexpression of VEGF-C improves tumor-immune surveillance and response to immunotherapy. Similar approaches in the context of the central nervous system have raised the exciting prospect that boosting lymphatic transport through VEGF-C delivery may improve neurodegeneration (151, 152) and traumatic brain injury (153). VEGF-C, however, has pleiotropic effects on lymphatic and blood vessels, as well as recruited myeloid cells, and it remains unclear what the relative contribution of each of these players may be to the therapeutic effects observed. Furthermore, at least in a vascularized tissue, rapid and potent immunity can be achieved in the absence of VEGF-C driven lymphangiogenesis (40) and DC trafficking proceeds even in the face of severe lymphatic hypoplasia (154). Therefore, therapeutic approaches to boost immune surveillance or reduce chronic inflammation may not need to necessarily focus on hyperproliferative vessel growth. Importantly, the data we discuss above paints a less binary picture of lymphatic transport, where its plasticity and transient responsiveness to inflammatory context is required for both the activation and resolution of inflammatory insult. Given the vast array of mechanisms through which lymphatic vessels regulate the inflammatory state of the peripheral tissues that they drain, a nuanced approach to manipulating their function is likely warranted. While there is clearly a therapeutic opportunity to target lymphatic vessels for immune benefit across disease states, there is also much to understand about normal and inflamed lymphatic vessel function and its multifaceted roles in immunity to inform these approaches.
Acknowledgments
Grant Support
AWL is supported by NIH/NCI (R01CA238163; P50CA225450), American Cancer Society (RSG-18-169-01-LIB), the Cancer Research Institute (Lloyd J. Old STAR Award), and The Mark Foundation for Cancer Research (Emerging Leader Award). MMS received support from NIH/NCI Basis of Skin/Mucosa Pathobiology Training Grant (5T32CA106195-15).
References:
- 1.Oliver G, Kipnis J, Randolph GJ, and Harvey NL. 2020. The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease. Cell 182: 270–296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Petrova TV, and Koh GY. 2020. Biological functions of lymphatic vessels. Science 369: eaax4063. [DOI] [PubMed] [Google Scholar]
- 3.Santambrogio L 2018. Lymph Formation and Composition. Lymphedema 139–152. [Google Scholar]
- 4.Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, Butz S, Vestweber D, Corada M, Molendini C, Dejana E, and McDonald DM. 2007. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med 204: 2349–2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pflicke H, and Sixt M. 2009. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med 206: 2925–2935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wiig H, and Swartz MA. 2012. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol. Rev. 92: 1005–1060. [DOI] [PubMed] [Google Scholar]
- 7.Triacca Valentina, Güç Esra, Kilarski Witold W, Pisano Marco, and Swartz Melody A. 2017. Transcellular Pathways in Lymphatic Endothelial Cells Regulate Changes in Solute Transport by Fluid Stress. Circulation Research 120: 1440–1452. [DOI] [PubMed] [Google Scholar]
- 8.Zawieja DC, Thangaswamy S, Wang W, Furtado R, Clement CC, Papadopoulos Z, Vigano M, Bridenbaugh EA, Zolla L, Gashev AA, Kipnis J, Lauvau G, and Santambrogio L. 2019. Lymphatic Cannulation for Lymph Sampling and Molecular Delivery. The Journal of Immunology 203: 2339–2350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jalkanen S, and Salmi M. 2020. Lymphatic endothelial cells of the lymph node. Nat Rev Immunol 20: 566–578. [DOI] [PubMed] [Google Scholar]
- 10.O’Melia MJ, Lund AW, and Thomas SN. 2019. The Biophysics of Lymphatic Transport: Engineering Tools and Immunological Consequences. iScience 22: 28–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Smith JB, McIntosh GH, and Morris B. 1970. The traffic of cells through tissues: a study of peripheral lymph in sheep. J Anat 107: 87–100. [PMC free article] [PubMed] [Google Scholar]
- 12.Mackay CR, Kimpton WG, Brandon MR, and Cahill RN. 1988. Lymphocyte subsets show marked differences in their distribution between blood and the afferent and efferent lymph of peripheral lymph nodes. J. Exp. Med. 167: 1755–1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Brown MN, Fintushel SR, Lee MH, Jennrich S, Geherin SA, Hay JB, Butcher EC, and Debes GF. 2010. Chemoattractant receptors and lymphocyte egress from extralymphoid tissue: changing requirements during the course of inflammation. J. Immunol. 185: 4873–4882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Geherin SA, Fintushel SR, Lee MH, Wilson RP, Patel RT, Alt C, Young AJ, Hay JB, and Debes GF. 2012. The Skin, a Novel Niche for Recirculating B Cells. The Journal of Immunology 188: 6027–6035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Yawalkar N, Hunger RE, Pichler WJ, Braathen LR, and Brand CU. 2000. Human afferent lymph from normal skin contains an increased number of mainly memory / effector CD4+ T cells expressing activation, adhesion and co-stimulatory molecules. European Journal of Immunology 30: 491–497. [DOI] [PubMed] [Google Scholar]
- 16.Olszewski WL, Grzelak I, Ziolkowska A, and Engeset A. 1995. Immune cell traffic from blood through the normal human skin to lymphatics. Clinics in Dermatology 13: 473–483. [DOI] [PubMed] [Google Scholar]
- 17.Morton AM, Sefik E, Upadhyay R, Weissleder R, Benoist C, and Mathis D. 2014. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. PNAS 111: 6696–6701. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Tomura M, Honda T, Tanizaki H, Otsuka A, Egawa G, Tokura Y, Waldmann H, Hori S, Cyster JG, Watanabe T, Miyachi Y, Kanagawa O, and Kabashima K. 2010. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J. Clin. Invest. 120: 883–893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mackay CR, Marston WL, and Dudler L. 1990. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171: 801–817. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mackay CR, Marston WL, Dudler L, Spertini O, Tedder TF, and Hein WR. 1992. Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. European Journal of Immunology 22: 887–895. [DOI] [PubMed] [Google Scholar]
- 21.Ono S, Egawa G, and Kabashima K. 2017. Regulation of blood vascular permeability in the skin. Inflamm Regener 37: 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Komarova Y, and Malik AB. 2010. Regulation of Endothelial Permeability via Paracellular and Transcellular Transport Pathways. Annu. Rev. Physiol. 72: 463–493. [DOI] [PubMed] [Google Scholar]
- 23.Guo M, Breslin JW, Wu MH, Gottardi CJ, and Yuan SY. 2008. VE-cadherin and β-catenin binding dynamics during histamine-induced endothelial hyperpermeability. American Journal of Physiology-Cell Physiology 294: C977–C984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Iijima N, and Iwasaki A. 2016. Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help. Nature 533: 552–556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fox JLR, and von Der Weid P-Y. 2002. Effects of histamine on the contractile and electrical activity in isolated lymphatic vessels of the guinea-pig mesentery: Histamine effects on lymphatic vessel activity. British Journal of Pharmacology 136: 1210–1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Reeder LB, DeFilippi VJ, and Ferguson MK. 1996. Characterization of the effects of histamine in porcine tracheobronchial lymph vessels. American Journal of Physiology-Heart and Circulatory Physiology 271: H2501–H2507. [DOI] [PubMed] [Google Scholar]
- 27.von der Weid P-Y, Zhao J, and Van Helden DF. 2001. Nitric oxide decreases pacemaker activity in lymphatic vessels of guinea pig mesentery. American Journal of Physiology-Heart and Circulatory Physiology 280: H2707–H2716. [DOI] [PubMed] [Google Scholar]
- 28.Gashev AA, Davis MJ, and Zawieja DC. 2002. Inhibition of the active lymph pump by flow in rat mesenteric lymphatics and thoracic duct. The Journal of Physiology 540: 1023–1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Avraham T, Zampell JC, Yan A, Elhadad S, Weitman ES, Rockson SG, Bromberg J, and Mehrara BJ. 2013. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB j. 27: 1114–1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.García Nores GD, Ly CL, Cuzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ, Gardenier JC, Savetsky IL, Nitti MD, Yu JZ, Rehal S, and Mehrara BJ. 2018. CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9: 1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Liao S, Cheng G, Conner DA, Huang Y, Kucherlapati RS, Munn LL, Ruddle NH, Jain RK, Fukumura D, and Padera TP. 2011. Impaired lymphatic contraction associated with immunosuppression. Proceedings of the National Academy of Sciences 108: 18784–18789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gasheva OY, Knippa K, Nepiushchikh ZV, Muthuchamy M, and Gashev AA. 2007. Age-related alterations of active pumping mechanisms in rat thoracic duct. Microcirculation 14: 827–839. [DOI] [PubMed] [Google Scholar]
- 33.Jones D, Meijer EFJ, Blatter C, Liao S, Pereira ER, Bouta EM, Jung K, Chin SM, Huang P, Munn LL, Vakoc BJ, Otto M, and Padera TP. 2018. Methicillin-resistant Staphylococcus aureus causes sustained collecting lymphatic vessel dysfunction. Sci Transl Med 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Fonseca D. M. da, Hand TW, Han S-J, Gerner MY, Zaretsky AG, Byrd AL, Harrison OJ, Ortiz AM, Quinones M, Trinchieri G, Brenchley JM, Brodsky IE, Germain RN, Randolph GJ, and Belkaid Y. 2015. Microbiota-Dependent Sequelae of Acute Infection Compromise Tissue-Specific Immunity. Cell 163: 354–366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.de Godoy JM, de Godoy MF, Valente A, Camacho EL, and Paiva EV. 2000. Lymphoscintigraphic evaluation in patients after erysipelas. Lymphology 33: 177–180. [PubMed] [Google Scholar]
- 36.Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, and Wade JC. 2005. Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. Clinical Infectious Diseases 41: 1373–1406. [DOI] [PubMed] [Google Scholar]
- 37.Yao L-C, Baluk P, Srinivasan RS, Oliver G, and McDonald DM. 2012. Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation. Am. J. Pathol. 180: 2561–2575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Suh SH, Choe K, Hong SP, Jeong S, Mäkinen T, Kim KS, Alitalo K, Surh CD, Koh GY, and Song J. 2019. Gut microbiota regulates lacteal integrity by inducing VEGF‐C in intestinal villus macrophages. EMBO Rep 20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Zhang F, Zarkada G, Han J, Li J, Dubrac A, Ola R, Genet G, Boyé K, Michon P, Künzel SE, Camporez JP, Singh AK, Fong G-H, Simons M, Tso P, Fernández-Hernando C, Shulman GI, Sessa WC, and Eichmann A. 2018. Lacteal junction zippering protects against diet-induced obesity. Science 361: 599–603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Loo CP, Nelson NA, Lane RS, Booth JL, Loprinzi Hardin SC, Thomas A, Slifka MK, Nolz JC, and Lund AW. 2017. Lymphatic Vessels Balance Viral Dissemination and Immune Activation following Cutaneous Viral Infection. Cell Rep 20: 3176–3187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, and Germain RN. 2012. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 150: 1235–1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, Fink K, Henrickson SE, Shayakhmetov DM, Di Paolo NC, van Rooijen N, Mempel TR, Whelan SP, and von Andrian UH. 2007. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450: 110–114. [DOI] [PubMed] [Google Scholar]
- 43.Gerner MY, Torabi-Parizi P, and Germain RN. 2015. Strategically Localized Dendritic Cells Promote Rapid T Cell Responses to Lymph-Borne Particulate Antigens. Immunity 42: 172–185. [DOI] [PubMed] [Google Scholar]
- 44.Hickman HD, Takeda K, Skon CN, Murray FR, Hensley SE, Loomis J, Barber GN, Bennink JR, and Yewdell JW. 2008. Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nature Immunology 9: 155–165. [DOI] [PubMed] [Google Scholar]
- 45.Lee HK, Zamora M, Linehan MM, Iijima N, Gonzalez D, Haberman A, and Iwasaki A. 2009. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. The Journal of Experimental Medicine 206: 359–370. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Chary SR, and Jain RK. 1989. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proceedings of the National Academy of Sciences 86: 5385–5389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Boardman KC, and Swartz MA. 2003. Interstitial Flow as a Guide for Lymphangiogenesis. Circulation Research 92: 801–808. [DOI] [PubMed] [Google Scholar]
- 48.Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, and Swartz MA. 2007. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11: 526–538. [DOI] [PubMed] [Google Scholar]
- 49.Ng CP, and Swartz MA. 2006. Mechanisms of Interstitial Flow-Induced Remodeling of Fibroblast–Collagen Cultures. Ann Biomed Eng 34: 446–454. [DOI] [PubMed] [Google Scholar]
- 50.Tomei AA, Siegert S, Britschgi MR, Luther SA, and Swartz MA. 2009. Fluid Flow Regulates Stromal Cell Organization and CCL21 Expression in a Tissue-Engineered Lymph Node Microenvironment. The Journal of Immunology 183: 4273–4283. [DOI] [PubMed] [Google Scholar]
- 51.Miteva DO, Rutkowski JM, Dixon JB, Kilarski W, Shields JD, and Swartz MA. 2010. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ. Res. 106: 920–931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, Zwirner J, Blankenstein T, Henning G, and Förster R. 2004. CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions. Immunity 21: 279–288. [DOI] [PubMed] [Google Scholar]
- 53.Martín-Fontecha A, Sebastiani S, Höpken UE, Uguccioni M, Lipp M, Lanzavecchia A, and Sallusto F. 2003. Regulation of Dendritic Cell Migration to the Draining Lymph Node. Journal of Experimental Medicine 198: 615–621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Johnson LA, and Jackson DG. 2010. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. International Immunology 22: 839–849. [DOI] [PubMed] [Google Scholar]
- 55.Vaahtomeri K, Brown M, Hauschild R, De Vries I, Leithner AF, Mehling M, Kaufmann WA, and Sixt M. 2017. Locally Triggered Release of the Chemokine CCL21 Promotes Dendritic Cell Transmigration across Lymphatic Endothelia. Cell Reports 19: 902–909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, Luther SA, Bollenbach T, and Sixt M. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339: 328–332. [DOI] [PubMed] [Google Scholar]
- 57.Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, Ng LG, Angeli V, and Shakhar G. 2011. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J. Exp. Med. 208: 2141–2153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Lucas ED, Schafer JB, Matsuda J, Kraus M, Burchill MA, and Tamburini BAJ. 2020. PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity. Cell Reports 33: 108258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, Lew AM, Shortman K, Heath WR, and Carbone FR. 2006. Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming. Immunity 25: 153–162. [DOI] [PubMed] [Google Scholar]
- 60.Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, Allan RS, Wojtasiak M, Shortman K, Carbone FR, Brooks AG, and Heath WR. 2009. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nature Immunology 10: 488–495. [DOI] [PubMed] [Google Scholar]
- 61.Jang MH, Sougawa N, Tanaka T, Hirata T, Hiroi T, Tohya K, Guo Z, Umemoto E, Ebisuno Y, Yang B-G, Seoh J-Y, Lipp M, Kiyono H, and Miyasaka M. 2006. CCR7 Is Critically Important for Migration of Dendritic Cells in Intestinal Lamina Propria to Mesenteric Lymph Nodes. The Journal of Immunology 176: 803–810. [DOI] [PubMed] [Google Scholar]
- 62.Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, and Krummel MF. 2016. Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell 30: 324–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, and Swartz MA. 2016. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest 126: 3389–3402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Sokol CL, Camire RB, Jones MC, and Luster AD. 2018. The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response. Immunity 49: 449–463.e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Vigl B, Aebischer D, Nitschké M, Iolyeva M, Röthlin T, Antsiferova O, and Halin C. 2011. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood 118: 205–215. [DOI] [PubMed] [Google Scholar]
- 66.Farnsworth RH, Karnezis T, Maciburko SJ, Mueller SN, and Stacker SA. 2019. The Interplay Between Lymphatic Vessels and Chemokines. Frontiers in Immunology 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Pegu A, Qin S, Fallert Junecko BA, Nisato RE, Pepper MS, and Reinhart TA. 2008. Human Lymphatic Endothelial Cells Express Multiple Functional TLRs. The Journal of Immunology 180: 3399–3405. [DOI] [PubMed] [Google Scholar]
- 68.Kabashima K, Shiraishi N, Sugita K, Mori T, Onoue A, Kobayashi M, Sakabe J, Yoshiki R, Tamamura H, Fujii N, Inaba K, and Tokura Y. 2007. CXCL12-CXCR4 Engagement Is Required for Migration of Cutaneous Dendritic Cells. The American Journal of Pathology 171: 1249–1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Schwab SR 2005. Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients. Science 309: 1735–1739. [DOI] [PubMed] [Google Scholar]
- 70.Czeloth N, Bernhardt G, Hofmann F, Genth H, and Förster R. 2005. Sphingosine-1-Phosphate Mediates Migration of Mature Dendritic Cells. The Journal of Immunology 175: 2960–2967. [DOI] [PubMed] [Google Scholar]
- 71.Idzko M, Hammad H, van Nimwegen M, Kool M, Müller T, Soullié T, Willart MAM, Hijdra D, Hoogsteden HC, and Lambrecht BN. 2006. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 116: 2935–2944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Pham THM, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, Coughlin SR, McDonald DM, Schwab SR, and Cyster JG. 2010. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 207: 17–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng Y-W, Huang Y, Cyster JG, and Coughlin SR. 2007. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate. Science 316: 295–298. [DOI] [PubMed] [Google Scholar]
- 74.Rathinasamy A, Czeloth N, Pabst O, Förster R, and Bernhardt G. 2010. The Origin and Maturity of Dendritic Cells Determine the Pattern of Sphingosine 1-Phosphate Receptors Expressed and Required for Efficient Migration. The Journal of Immunology 185: 4072–4081. [DOI] [PubMed] [Google Scholar]
- 75.Bryce SA, Wilson RAM, Tiplady EM, Asquith DL, Bromley SK, Luster AD, Graham GJ, and Nibbs RJB. 2016. ACKR4 on Stromal Cells Scavenges CCL19 To Enable CCR7-Dependent Trafficking of APCs from Inflamed Skin to Lymph Nodes. The Journal of Immunology 196: 3341–3353. [DOI] [PubMed] [Google Scholar]
- 76.Nibbs RJB, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JDM, Henderson A, Kerjaschki D, Maurer D, Graham GJ, and Rot A. 2001. The β-Chemokine Receptor D6 Is Expressed by Lymphatic Endothelium and a Subset of Vascular Tumors. The American Journal of Pathology 158: 867–877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.McKimmie CS, Singh MD, Hewit K, Lopez-Franco O, Le Brocq M, Rose-John S, Lee KM, Baker AH, Wheat R, Blackbourn DJ, Nibbs RJB, and Graham GJ. 2013. An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood 121: 3768–3777. [DOI] [PubMed] [Google Scholar]
- 78.Lee KM, McKimmie CS, Gilchrist DS, Pallas KJ, Nibbs RJ, Garside P, McDonald V, Jenkins C, Ransohoff R, Liu L, Milling S, Cerovic V, and Graham GJ. 2011. D6 facilitates cellular migration and fluid flow to lymph nodes by suppressing lymphatic congestion. Blood 118: 6220–6229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.de la Torre Y, Locati M, Buracchi C, Dupor J, Cook D, Bonecchi R, Nebuloni M, Rukavina D, Vago L, Vecchi A, Lira S, and Mantovani A. 2005. Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur. J. Immunol. 35: 1342–1346. [DOI] [PubMed] [Google Scholar]
- 80.Lämmermann T, Bader BL, Monkley SJ, Worbs T, Wedlich-Söldner R, Hirsch K, Keller M, Förster R, Critchley DR, Fässler R, and Sixt M. 2008. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 453: 51–55. [DOI] [PubMed] [Google Scholar]
- 81.Johnson LA, Clasper S, Holt AP, Lalor PF, Baban D, and Jackson DG. 2006. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 203: 2763–2777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Vigl B, Aebischer D, Nitschké M, Iolyeva M, Röthlin T, Antsiferova O, and Halin C. 2011. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood 118: 205–215. [DOI] [PubMed] [Google Scholar]
- 83.Podgrabinska S, Kamalu O, Mayer L, Shimaoka M, Snoeck H, Randolph GJ, and Skobe M. 2009. Inflamed Lymphatic Endothelium Suppresses Dendritic Cell Maturation and Function via Mac-1/ICAM-1-Dependent Mechanism. The Journal of Immunology 183: 1767–1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Teijeira Á, Garasa S, Peláez R, Azpilikueta A, Ochoa C, Marré D, Rodrigues M, Alfaro C, Aubá C, Valitutti S, Melero I, and Rouzaut A. 2013. Lymphatic Endothelium Forms Integrin-Engaging 3D Structures during DC Transit across Inflamed Lymphatic Vessels. Journal of Investigative Dermatology 133: 2276–2285. [DOI] [PubMed] [Google Scholar]
- 85.Xu H, Guan H, Zu G, Bullard D, Hanson J, Slater M, and Elmets CA. 2001. The role of ICAM-1 molecule in the migration of Langerhans cells in the skin and regional lymph node. European Journal of Immunology 31: 3085–3093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Teoh D, Johnson LA, Hanke T, McMichael AJ, and Jackson DG. 2009. Blocking Development of a CD8+ T Cell Response by Targeting Lymphatic Recruitment of APC. The Journal of Immunology 182: 2425–2431. [DOI] [PubMed] [Google Scholar]
- 87.Johnson LA, Banerji S, Lawrance W, Gileadi U, Prota G, Holder KA, Roshorm YM, Hanke T, Cerundolo V, Gale NW, and Jackson DG. 2017. Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nature Immunology 18: 762–770. [DOI] [PubMed] [Google Scholar]
- 88.Nitschké M, Aebischer D, Abadier M, Haener S, Lucic M, Vigl B, Luche H, Fehling HJ, Biehlmaier O, Lyck R, and Halin C. 2012. Differential requirement for ROCK in dendritic cell migration within lymphatic capillaries in steady-state and inflammation. Blood 120: 2249–2258. [DOI] [PubMed] [Google Scholar]
- 89.Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, Ng LG, Angeli V, and Shakhar G. 2011. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med 208: 2141–2153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Teijeira A, Hunter MC, Russo E, Proulx ST, Frei T, Debes GF, Coles M, Melero I, Detmar M, Rouzaut A, and Halin C. 2017. T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions. Cell Reports 18: 857–865. [DOI] [PubMed] [Google Scholar]
- 91.Hunter MC, Teijeira A, Montecchi R, Russo E, Runge P, Kiefer F, and Halin C. 2019. Dendritic Cells and T Cells Interact Within Murine Afferent Lymphatic Capillaries. Frontiers in Immunology 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Haig DM, Hopkins J, and Miller HRP. 1999. Local immune responses in afferent and efferent lymph. Immunology 96: 155–163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Smith JB, McIntosh GH, and Morris B. 1970. The migration of cells through chronically inflamed tissues. The Journal of Pathology 100: 21–29. [DOI] [PubMed] [Google Scholar]
- 94.Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, and Swartz MA. 2012. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1: 191–199. [DOI] [PubMed] [Google Scholar]
- 95.Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, and Detmar M. 2010. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 207: 2255–2269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.D’Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L, Fiocchi C, and Danese S. 2014. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J. Clin. Invest. 124: 3863–3878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Weinkopff T, Konradt C, Christian DA, Discher DE, Hunter CA, and Scott P. 2016. Leishmania major Infection–Induced VEGF-A/VEGFR-2 Signaling Promotes Lymphangiogenesis That Controls Disease. The Journal of Immunology 197: 1823–1831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry M-L, Magistrelli G, Masternak K, Chevailler A, Delneste Y, and Jeannin P. 2011. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood 117: 1196–1204. [DOI] [PubMed] [Google Scholar]
- 99.Arokiasamy S, Zakian C, Dilliway J, Wang W, Nourshargh S, and Voisin M-B. 2017. Endogenous TNFα orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation. Scientific Reports 7: 44189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Hampton HR, Bailey J, Tomura M, Brink R, and Chtanova T. 2015. Microbe-dependent lymphatic migration of neutrophils modulates lymphocyte proliferation in lymph nodes. Nature Communications 6: 7139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Rigby DA, Ferguson DJP, Johnson LA, and Jackson DG. 2015. Neutrophils rapidly transit inflamed lymphatic vessel endothelium via integrin-dependent proteolysis and lipoxin-induced junctional retraction. Journal of Leukocyte Biology 98: 897–912. [DOI] [PubMed] [Google Scholar]
- 102.Gorlino CV, Ranocchia RP, Harman MF, García IA, Crespo MI, Morón G, Maletto BA, and Pistoresi-Palencia MC. 2014. Neutrophils Exhibit Differential Requirements for Homing Molecules in Their Lymphatic and Blood Trafficking into Draining Lymph Nodes. The Journal of Immunology 193: 1966–1974. [DOI] [PubMed] [Google Scholar]
- 103.Geherin SA, Fintushel SR, Lee MH, Wilson RP, Patel RT, Alt C, Young AJ, Hay JB, and Debes GF. 2012. The Skin, a Novel Niche for Recirculating B Cells. The Journal of Immunology 188: 6027–6035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Brown MN, Fintushel SR, Lee MH, Jennrich S, Geherin SA, Hay JB, Butcher EC, and Debes GF. 2010. Chemoattractant Receptors and Lymphocyte Egress from Extralymphoid Tissue: Changing Requirements during the Course of Inflammation. The Journal of Immunology 185: 4873–4882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Bonneau M, Epardaud M, Payot F, Niborski V, Thoulouze M-I, Bernex F, Charley B, Riffault S, Guilloteau LA, and Schwartz‐Cornil I. 2006. Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymph node. Journal of Leukocyte Biology 79: 268–276. [DOI] [PubMed] [Google Scholar]
- 106.Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, Ivanov S, Duan Q, Bala S, Condon T, van Rooijen N, Grainger JR, Belkaid Y, Ma’ayan A, Riches DWH, Yokoyama WM, Ginhoux F, Henson PM, and Randolph GJ. 2013. Minimal Differentiation of Classical Monocytes as They Survey Steady-State Tissues and Transport Antigen to Lymph Nodes. Immunity 39: 599–610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Hayes AJ, Rane S, Scales HE, Meehan GR, Benson RA, Maroof A, Schroeder J, Tomura M, Gozzard N, Yates AJ, Garside P, and Brewer JM. 2019. Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity. Front. Immunol. 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Neeland MR, Elhay MJ, Nathanielsz J, Meeusen ENT, and de Veer MJ. 2014. Incorporation of CpG into a Liposomal Vaccine Formulation Increases the Maturation of Antigen-Loaded Dendritic Cells and Monocytes To Improve Local and Systemic Immunity. The Journal of Immunology. [DOI] [PubMed] [Google Scholar]
- 109.Becker HM, Rullo J, Chen M, Ghazarian M, Bak S, Xiao H, Hay JB, and Cybulsky MI. 2013. α1β1 Integrin-Mediated Adhesion Inhibits Macrophage Exit from a Peripheral Inflammatory Lesion. The Journal of Immunology. [DOI] [PubMed] [Google Scholar]
- 110.Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, and Butcher EC. 2005. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 6: 889–894. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Bromley SK, Thomas SY, and Luster AD. 2005. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nature Immunology 6: 895–901. [DOI] [PubMed] [Google Scholar]
- 112.Jennrich S, Lee MH, Lynn RC, Dewberry K, and Debes GF. 2012. Tissue exit: a novel control point in the accumulation of antigen-specific CD8 T cells in the influenza a virus-infected lung. J. Virol. 86: 3436–3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Gómez D, Diehl MC, Crosby EJ, Weinkopff T, and Debes GF. 2015. Effector T Cell Egress via Afferent Lymph Modulates Local Tissue Inflammation. J.I. 195: 3531–3536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Torcellan T, Hampton HR, Bailey J, Tomura M, Brink R, and Chtanova T. 2017. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Proceedings of the National Academy of Sciences 114: 5677–5682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Geherin SA, Wilson RP, Jennrich S, and Debes GF. 2014. CXCR4 Is Dispensable for T Cell Egress from Chronically Inflamed Skin via the Afferent Lymph. PLoS ONE 9: e95626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Karikoski M, Irjala H, Maksimow M, Miiluniemi M, Granfors K, Hernesniemi S, Elima K, Moldenhauer G, Schledzewski K, Kzhyshkowska J, Goerdt S, Salmi M, and Jalkanen S. 2009. Clever-1/Stabilin-1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation. European Journal of Immunology 39: 3477–3487. [DOI] [PubMed] [Google Scholar]
- 117.Marko Salmi, Marika Karikoski, Kati Elima, Pia Rantakari, and Sirpa Jalkanen. 2013. CD44 Binds to Macrophage Mannose Receptor on Lymphatic Endothelium and Supports Lymphocyte Migration via Afferent Lymphatics. Circulation Research 112: 1577–1582. [DOI] [PubMed] [Google Scholar]
- 118.Vrieling M, Santema W, Rhijn IV, Rutten V, and Koets A. 2012. γδ T Cell Homing to Skin and Migration to Skin-Draining Lymph Nodes Is CCR7 Independent. The Journal of Immunology 188: 578–584. [DOI] [PubMed] [Google Scholar]
- 119.Geherin SA, Lee MH, Wilson RP, and Debes GF. 2013. Ovine skin-recirculating γδ T cells express IFN-γ and IL-17 and exit tissue independently of CCR7. Veterinary Immunology and Immunopathology 155: 87–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Steele M, Churchill M, Breazeale A, Lane RS, Nelson NA, and Lund AW. 2019. Quantifying Leukocyte Egress from Murine Skin and Tumors. Journal of Visualized Experiments: JoVE 143. [DOI] [PubMed] [Google Scholar]
- 121.Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, Merad M, Peche H, Lira SA, Ding Y, Yang Y, He X, Schuchman EH, Allende ML, Ochando JC, and Bromberg JS. 2008. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nature Immunology 9: 42–53. [DOI] [PubMed] [Google Scholar]
- 122.Xiong Y, Piao W, Brinkman CC, Li L, Kulinski JM, Olivera A, Cartier A, Hla T, Hippen KL, Blazar BR, Schwab SR, and Bromberg JS. 2019. CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. Sci. Immunol. 4: eaav1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Cartier A, Leigh T, Liu CH, and Hla T. 2020. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci USA 117: 3157–3166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Jung B, Obinata H, Galvani S, Mendelson K, Ding B, Skoura A, Kinzel B, Brinkmann V, Rafii S, Evans T, and Hla T. 2012. Flow-Regulated Endothelial S1P Receptor-1 Signaling Sustains Vascular Development. Developmental Cell 23: 600–610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon M-L, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, Tscharke DC, Heath WR, Inouye M, Carbone FR, and Gebhardt T. 2013. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nature Immunology 14: 1294–1301. [DOI] [PubMed] [Google Scholar]
- 126.Skon CN, Lee J-Y, Anderson KG, Masopust D, Hogquist KA, and Jameson SC. 2013. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nature Immunology 14: 1285–1293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, Carbone FR, and Gebhardt T. 2015. Cutting Edge: CD69 Interference with Sphingosine-1-Phosphate Receptor Function Regulates Peripheral T Cell Retention. The Journal of Immunology 194: 2059–2063. [DOI] [PubMed] [Google Scholar]
- 128.Khan TN, Mooster JL, Kilgore AM, Osborn JF, and Nolz JC. 2016. Local antigen in nonlymphoid tissue promotes resident memory CD8 + T cell formation during viral infection. The Journal of Experimental Medicine jem.20151855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Debes GF, Bonhagen K, Wolff T, Kretschmer U, Krautwald S, Kamradt T, and Hamann A. 2004. CC Chemokine Receptor 7 Expression by Effector/Memory CD4+ T Cells Depends on Antigen Specificity and Tissue Localization during Influenza A Virus Infection. JVI 78: 7528–7535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Schaeuble K, Hauser MA, Singer E, Groettrup M, and Legler DF. 2011. Cross-Talk Between TCR and CCR7 Signaling Sets a Temporal Threshold for Enhanced T Lymphocyte Migration. J.I. 187: 5645–5652. [DOI] [PubMed] [Google Scholar]
- 131.Zhang N, Schröppel B, Lal G, Jakubzick C, Mao X, Chen D, Yin N, Jessberger R, Ochando JC, Ding Y, and Bromberg JS. 2009. Regulatory T Cells Sequentially Migrate from Inflamed Tissues to Draining Lymph Nodes to Suppress the Alloimmune Response. Immunity 30: 458–469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Brinkman CC, Iwami D, Hritzo MK, Xiong Y, Ahmad S, Simon T, Hippen KL, Blazar BR, and Bromberg JS. 2016. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nature Communications 7: 12021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Piao W, Xiong Y, Li L, Saxena V, Smith KD, Hippen KL, Paluskievicz C, Willsonshirkey M, Blazar BR, Abdi R, and Bromberg JS. 2020. Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration. Cell Reports 30: 1052–1062.e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Lane RS, Femel J, Breazeale AP, Loo CP, Thibault G, Kaempf A, Mori M, Tsujikawa T, Chang YH, and Lund AW. 2018. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J. Exp. Med. 215: 3057–3074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, and Kerjaschki D. 2002. Tumor-Associated Macrophages Express Lymphatic Endothelial Growth Factors and Are Related to Peritumoral Lymphangiogenesis. The American Journal of Pathology 161: 947–956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, and Detmar M. 2001. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159: 893–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Kajiya K, Sawane M, Huggenberger R, and Detmar M. 2009. Activation of the VEGFR-3 Pathway by VEGF-C Attenuates UVB-Induced Edema Formation and Skin Inflammation by Promoting Lymphangiogenesis. Journal of Investigative Dermatology 129: 1292–1298. [DOI] [PubMed] [Google Scholar]
- 138.Jurisic G, Sundberg JP, and Detmar M. 2013. Blockade of VEGF Receptor-3 Aggravates Inflammatory Bowel Disease and Lymphatic Vessel Enlargement. Inflamm Bowel Dis 19: 1983–1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Liao S, and von der Weid P-Y. 2014. Inflammation-induced lymphangiogenesis and lymphatic dysfunction. Angiogenesis 17: 325–334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Angeli V, Ginhoux F, Llodrà J, Quemeneur L, Frenette PS, Skobe M, Jessberger R, Merad M, and Randolph GJ. 2006. B Cell-Driven Lymphangiogenesis in Inflamed Lymph Nodes Enhances Dendritic Cell Mobilization. Immunity 24: 203–215. [DOI] [PubMed] [Google Scholar]
- 141.Kataru RP, Kim H, Jang C, Choi DK, Koh BI, Kim M, Gollamudi S, Kim Y-K, Lee S-H, and Koh GY. 2011. T Lymphocytes Negatively Regulate Lymph Node Lymphatic Vessel Formation. Immunity 34: 96–107. [DOI] [PubMed] [Google Scholar]
- 142.Lucas ED, Finlon JM, Burchill MA, McCarthy MK, Morrison TE, Colpitts TM, and Tamburini BAJ. 2018. Type 1 IFN and PD-L1 Coordinate Lymphatic Endothelial Cell Expansion and Contraction during an Inflammatory Immune Response. The Journal of Immunology 201: 1735–1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Ylä-Herttuala S, Jackson DG, Alitalo K, and McDonald DM. 2005. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 115: 247–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Lohela M, Heloterä H, Haiko P, Dumont DJ, and Alitalo K. 2008. Transgenic Induction of Vascular Endothelial Growth Factor-C Is Strongly Angiogenic in Mouse Embryos but Leads to Persistent Lymphatic Hyperplasia in Adult Tissues. The American Journal of Pathology 173: 1891–1901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Kelley PM, Steele MM, and Tempero RM. 2011. Regressed lymphatic vessels develop during corneal repair. Laboratory Investigation 91: 1643–1651. [DOI] [PubMed] [Google Scholar]
- 146.Cursiefen C, Maruyama K, Jackson DG, Streilein JW, and Kruse FE. 2006. Time Course of Angiogenesis and Lymphangiogenesis After Brief Corneal Inflammation. Cornea 25: 443–447. [DOI] [PubMed] [Google Scholar]
- 147.Kelley PM, Connor AL, and Tempero RM. 2013. Lymphatic Vessel Memory Stimulated by Recurrent Inflammation. The American Journal of Pathology 182: 2418–2428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Ordovas-Montanes J, Beyaz S, Rakoff-Nahoum S, and Shalek AK. 2020. Distribution and storage of inflammatory memory in barrier tissues. Nature Reviews Immunology 20: 308–320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, and Swartz MA. 2017. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Science Translational Medicine 9: eaal4712. [DOI] [PubMed] [Google Scholar]
- 150.Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, Alitalo K, Thomas J-L, and Iwasaki A. 2020. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, Herod SG, Knopp J, Setliff JC, Lupi AL, Da Mesquita S, Frost EL, Gaultier A, Harris TH, Cao R, Hu S, Lukens JR, Smirnov I, Overall CC, Oliver G, and Kipnis J. 2018. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21: 1380–1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE, Powell RD, Baker W, Dabhi N, Bai R, Cao R, Hu S, Rich SS, Munson JM, Lopes MB, Overall CC, Acton ST, and Kipnis J. 2018. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature 560: 185–191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Bolte AC, Dutta AB, Hurt ME, Smirnov I, Kovacs MA, McKee CA, Ennerfelt HE, Shapiro D, Nguyen BH, Frost EL, Lammert CR, Kipnis J, and Lukens JR. 2020. Meningeal lymphatic dysfunction exacerbates traumatic brain injury pathogenesis. Nat Commun 11: 4524. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Platt AM, Rutkowski JM, Martel C, Kuan EL, Ivanov S, Swartz MA, and Randolph GJ. 2013. Normal dendritic cell mobilization to lymph nodes under conditions of severe lymphatic hypoplasia. J. Immunol. 190: 4608–4620. [DOI] [PMC free article] [PubMed] [Google Scholar]


